Is a complete IONS research report available?

No complete published report is available for Ionis Pharmaceuticals, Inc. (IONS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Ionis Pharmaceuticals, Inc. (IONS)

NASDAQ: IONS · USD

$54.0

-1.26 (-2.3%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first IONS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	8.9B
Revenue (ttm)	873.7M
Net income (ttm)	-565.4M
EPS (ttm)	-$3.47
Shares out	165.3M
Volume	3,129,417
Beta	0.37
Price target	$90.9	+68.2%

Market data

Price

Recent price action with selectable time range.

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All IONS indicators

Market & fundamental data

Available fields

222

Groups with data

Currency

USD

Showing 222 of 222 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000874015
Company name	Ionis Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	462222100
Employees	1,402
Employees Change	333%
Employees Change Percent	31.15
Enterprise value	$9.3B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1991-05-17
Isin	US4622221004
Last refreshed	2026-07-30
Market cap	$8.9B
Market cap category	Mid-Cap
Price	$54.04
Price currency	USD
Rev Per Employee	623,189.02x
Sector	Healthcare
Sector PE	45.63
Sector PE Fwd	24.38
Sic	2834
Symbol	IONS
Website	https://www.ionis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-6.33%
EV Sales Forward	10.34x
EV/Sales	10.64x
FCF yield	-10.88%
P/B ratio	20.27x
P/S ratio	10.22x
PS Forward	9.94x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-11.67%
EBITDA Margin	-11.67%
Gross margin	-7.65%
Gross Profit	$-66.8M
Gross Profit Growth Q	-79.17%
Net Income	$-565.4M
Net Income Growth Quarters	1%
Net Income Growth Years	1%
Pretax Margin	-64.39%
Profit Margin	-64.71%
Profit Per Employee	$-403,272
ROA	-12.43
Roa5y	-7.19
ROCE	-3.81
ROE	-105.5
Roe5y	-56.83
ROIC	-61.72

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	6.48%
Cagr15y	12.97%
Cagr1y	31.29%
Cagr20y	11.57%
Cagr3y	10.74%
Cagr5y	7.45%
EPS Growth Quarters	1
EPS Growth Years	1
Revenue Growth	-7.45x
Revenue Growth Q	-40.71x
Revenue Growth Quarters	1x
Revenue Growth Years	1x
Revenue Growth3 Y	11.48x
Revenue Growth5 Y	4.9x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.29
Assets	$3B
Cash	$2.1B
Current Assets	$2.5B
Current Liabilities	$316M
Debt	$2.4B
Debt Equity	$5.5
Equity	$440M
Interest Coverage	-1.15
Liabilities	$2.6B
Long Term Assets	$503M
Long Term Liabilities	$2.2B
Net Cash	$-363M
Net Cash By Market Cap	$-4.06
Net Debt Equity	$0.83
Tangible Book Value	$440M
Tangible Book Value Per Share	$2.67
WACC	5.54

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.89
Net Working Capital	$363M
Quick ratio	6.69
Working Capital	$2.2B
Working Capital Turnover	$0.45

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.42%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	87.38%
1Y total return	31.26%
200-day SMA	75.34
3Y total return	35.81%
50-day SMA	70.28
50-day SMA vs 200-day SMA	50under200
5Y total return	43.23%
All Time High	86.74
All Time High Change	-37.7%
All Time High Date	2026-02-05
All Time Low	2.5
All Time Low Change	2,061.6%
All Time Low Date	2003-03-17
ATR	2.88
Beta	0.37
Beta1y	0.32
Beta2y	0.74
Ch YTD	-31.69
High	55.36
High52	86.74
High52 Date	2026-07-08
High52ch	-37.7%
Low	53.5
Low52	40.03
Low52 Date	2025-08-07
Low52ch	35%
Ma50ch	-23.1%
Premarket Change Percent	0.72
Premarket Price	$55.7
Premarket Volume	2,161
Price vs 200-day SMA	-28.27%
RSI	29.24
RSI Monthly	46.59
RSI Weekly	33.92
Sharpe ratio	0.69x
Sortino ratio	1.25
Total Return	-4.42%
Tr YTD	-31.69
Tr15y	523.3%
Tr1m	-33.43%
Tr1w	0.06%
Tr3m	-24.71%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	22
Analyst Count Top	16
Analyst Price Target Top	$92.71
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.95
Earnings Revenue Estimate	189,622,160x
Earnings Revenue Estimate Growth	-58.05x
Operating Income	$-594.7M
Operating margin	-68.06
Price target	$90.9
Price Target Change	$68.21
Price Target Change Top	$71.56

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	163,956,859%
Float Percent	99.21%
Net Borrowing	502,183,000
Shares Insiders	0.75%
Shares Institutions	105.45%
Shares Out	165,262,556
Shares Qo Q	0.08%
Shares Yo Y	4.42%
Short Float	12.22%
Short Ratio	5.18
Short Shares	12.13

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-1.1B
Adjusted OCF	-1,058,058,000
Average Volume	4,579,257.55x
Bv Per Share	2.67
CAPEX	$-60.6M
Ch10y	87.38
Ch15y	523.3
Ch1m	-33.43
Ch1w	0.06
Ch1y	31.26
Ch20y	793.2
Ch3m	-24.71
Ch3y	35.81
Ch5y	43.23
Ch6m	-34.03
Change	-2.28%
Change From Open	-1.91
Close	55.3
Days Gap	-0.38
Depreciation Amortization	14,697,000
Dollar Volume	169,113,694.7
Earnings Date	2026-07-29
Earnings Time	bmo
EBIT	$-102M
EBITDA	$-102M
EPS	$-3.47
F Score	1
FCF	$-971.3M
FCF EV Yield	-10.45x
FCF Per Share	$-5.88
Financing CF	730,899,000
Fiscal Year End	December
Founded	1,989
Income Tax	$2.8M
Investing CF	88,585,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-29
Last Report Date	2026-06-30
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	75.28
Ma150ch	-28.21%
Ma20	62.55
Ma20ch	-13.61%
Net CF	-90,811,000
Next Earnings Date	2026-10-28
Open	55.09
Optionable	Yes
Position In Range	29.03
Post Close	54.04
Postmarket Change Percent	-0
Postmarket Price	$54.04
Ppne	387,000,000
Pre Close	55.3
Price Date	2026-07-29
Ptbv Ratio	20.3
Relative Volume	0.68x
Revenue	873,711,000x
SBC By Revenue	13.93x
Share Based Comp	147,431,000
Tax By Revenue	0.32x
Tr20y	793.22%
Tr6m	-34.03%
Us State	California
Volume	3,129,417

Ionis Pharmaceuticals, Inc. (IONS)

Coverage state: Market snapshot only — no published research

Generate the first IONS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · IONS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IONS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on IONS

Frequently asked questions